TARSONS319.00

Tarsons Products Limited

· Pharma & Health
₹ CrorePeersFISCHERLAXMIDENTLFABTECHGKBMcap ₹1,697 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity6.964.722.262.26
Return on Assets4.392.761.211.21
Return on Capital Employed7.835.332.322.32
Return on Invested Capital4.893.431.410.99
Margins
EBITDA Margin33.6828.2227.9127.01
Operating Margin20.0412.295.065.06
Incremental Operating Margin-11.65-89.13
Pretax Margin20.5011.425.183.97
Net Income Margin14.397.593.392.51
FCF Margin-27.54-9.55-1.68-1.68
Additional
Effective Tax Rate29.8333.5534.6036.76
Dvd Payout Ratio0.0035.720.00
Sustainable Growth Rate6.963.032.262.26
Incremental Operating Margin %-11.65-89.13-30.75
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.